文献速递细胞病理与分子病理神经与头颈病理

2023版Bethesda甲状腺细胞病理报告系统在儿童队列中的表现:单中心经验

Performance of the 2023 Bethesda System for Reporting Thyroid Cytopathology in a pediatric cohort: a single-center experience.
PubMed 文献 · Hum Pathol · 2026-04-30

该单中心回顾性研究纳入63例年龄≤21岁患者的甲状腺细针穿刺(FNA)标本,按2023版TBSRTC分类并计算切除结节的观察性恶性风险(ROM)。Bethesda II、IV、V类的ROM与已发表的儿童数据大致一致,而Bethesda III类因仅3个结节被切除而估计不精确;整体恶性率为19/36(52.8%)。

要点

  • 2023版TBSRTC适用于儿童甲状腺FNA分类。
  • Bethesda II、IV、V类ROM与已发表儿童数据大致一致。
  • Bethesda III类因切除结节少(3例)而ROM估计不精确。

核心结论

  • 2023版TBSRTC在该儿童队列中具有适用性。
  • Bethesda II、IV和V类的ROM与已发表的儿童数据大致一致。
  • Bethesda III类因仅3个结节被切除而ROM估计不精确。

研究设计与样本

  • 单中心回顾性研究,回顾了63例年龄≤21岁患者的甲状腺FNA标本(2023年1月至2025年10月)。
  • 病例按2023版TBSRTC分类,对切除结节计算观察性ROM并给出精确95%CI。
  • Bethesda III类结节进一步分为AUS伴核异型性和AUS-其他。

主要发现

  • 诊断分布:Bethesda I类5/63(7.9%),II类32/63(50.8%),III类3/63(4.8%),IV类10/63(15.9%),V类13/63(20.6%),VI类0/63(0%)。
  • 36个结节有组织学随访,整体恶性率为19/36(52.8%)。
  • 切除结节的观察性ROM:Bethesda I类0/1(0.0%),II类1/11(9.1%),III类2/3(66.7%),IV类4/8(50.0%),V类12/13(92.3%)。
  • 两例恶性Bethesda III类结节均为AUS伴核异型性,AUS-其他病例为良性。

关键数值与推荐

  • Bethesda II类ROM为1/11(9.1%),IV类为4/8(50.0%),V类为12/13(92.3%),与已发表儿童数据大致一致。
  • Bethesda III类ROM为2/3(66.7%),因仅3个结节被切除而估计不精确。

临床怎么用

  • 在儿童甲状腺FNA报告中可采用2023版TBSRTC分类。
  • 对Bethesda III类结节,可参考AUS亚分类(伴核异型性 vs 其他)辅助风险评估。
  • 需更大规模多中心研究以完善儿童ROM估计。

局限性

  • 单中心回顾性设计,样本量有限(63例FNA,36例有组织学随访)。
  • Bethesda III类仅3个结节被切除,ROM估计不精确。
  • 需要更大规模多中心研究,采用标准化随访和明确的AUS亚分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric thyroid nodules are uncommon but have higher malignancy risk than adult nodules. The 2023 TBSRTC updated ROM estimates and expanded pediatric guidance, but data remain limited. METHODS: We reviewed 63 thyroid FNAs from patients aged 21 years or younger at a tertiary center (January 2023-October 2025). Cases were classified according to the 2023 TBSRTC. Observed ROM was calculated in resected nodules with exact 95% CIs. Bethesda III nodules were subclassified as AUS with nuclear atypia or AUS-other. RESULTS: Diagnoses were Bethesda I in 5/63 (7.9%), Bethesda II in 32/63 (50.8%), Bethesda III in 3/63 (4.8%), Bethesda IV in 10/63 (15.9%), Bethesda V in 13/63 (20.6%), and Bethesda VI in 0/63 (0%). Histologic follow-up was available for 36 nodules. Observed ROM among resected nodules was 0/1 (0.0%) for Bethesda I, 1/11 (9.1%) for Bethesda II, 2/3 (66.7%) for Bethesda III, 4/8 (50.0%) for Bethesda IV, and 12/13 (92.3%) for Bethesda V. The two malignant Bethesda III cases were AUS with nuclear atypia; the AUS-other case was benign. Overall malignant yield was 19/36 (52.8%). CONCLUSIONS: The 2023 TBSRTC was applicable in this pediatric cohort. Bethesda II, IV, and V ROM estimates were broadly consistent with published pediatric data, whereas Bethesda III was imprecise because only three nodules were resected. Larger multicenter studies with standardized follow-up and explicit AUS subclassification are needed.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Straccia P, Fiorentino V, Padial Urtueta B, et al. Performance of the 2023 Bethesda System for Reporting Thyroid Cytopathology in a pediatric cohort: a single-center experience. Hum Pathol. 2026. PMID: 42069008. doi:10.1016/j.humpath.2026.106139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。